Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company dedicated to developing novel therapies aimed at rebalancing inflammation to optimize health, announced today that the Nasdaq Stock Market LLC (“Nasdaq”) has formally notified the Company…
Lantern Pharma Publishes PCT Patent for AI Model Predicting BBB Permeability Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) company dedicated to advancing cancer therapies and transforming the efficiency and timeline of oncology drug discovery and development, has…
Ventus Therapeutics Names Dr. Mona Kotecha as Chief Medical Officer Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced the appointment of Mona Kotecha, M.D., as its new Chief Medical Officer (CMO). Ventus is advancing two novel small-molecule programs, VENT-03 and…
Celerion Expands UK Phase 1 Trials at Queen’s University Belfast’s iREACH Health Celerion, a global leader in early clinical research, has announced a strategic agreement to relocate its U.K. Phase 1 clinical research operations to the new iREACH Health facility…
Reverb Therapeutics Raises $12M to Advance Amplify•R™ Platform Reverb Therapeutics, a biotechnology company pioneering innovative approaches to harness the natural immune system and cytokine signaling for the treatment of life-threatening diseases, has announced the successful closing of a $12 million…
ICC Arbitral Tribunal Decides in Favor of AOP Health in Arbitration over BESREMi® (Ropeginterferon alfa-2b) A tribunal under the International Chamber of Commerce (ICC) issued a partial final award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its…
Pneuma Respiratory: Advancing Inhaled Therapeutics to Revolutionize Respiratory Health Pneuma Respiratory, a pioneering med-tech and pharmaceutical company, is breaking new ground in the field of inhaled respiratory therapeutics. With a strong commitment to improving the standard of care for millions…
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Updates Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company dedicated to developing innovative treatments for individuals suffering from acute cannabis-induced toxic effects, has…
Newleos Launches with $93.5M to Advance Neuropsychiatric Treatments Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and experienced leaders in CNS drug development, has announced the successful closing of an oversubscribed $93.5 million Series A financing. This…
Taiho Oncology Europe Announces Availability of Futibatinib in Italy for the Treatment of Cholangiocarcinoma Taiho Oncology Europe, a subsidiary of Taiho Pharmaceutical Co., Ltd., has officially announced the availability of futibatinib in Italy for the treatment of patients diagnosed with…
Incyte Announces Q4 and Full-Year 2024 Financial Results, Shares 2025 Guidance and R&D Milestones Incyte reported its financial results for the fourth quarter and full year ended December 31, 2024. The company also provided its financial outlook for 2025 and…
Bristol Myers Squibb (NYSE: BMY) has announced positive topline results from the Phase 2 TRANSCEND FL trial, evaluating Breyanzi® (lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma. The study met its primary endpoint in the…